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Abstract 32 
Cheese whey, also known as sweet whey, is a by-product of cheese-making that contains many 33 
valuable constituents. Among them, whey proteins stand out for their high nutritional value in terms 34 
of biological value and composition in essential amino acids. In recent years, the increasing demand 35 
for caprine and ovine cheeses has produced important amounts of whey from these species, 36 
boosting research on the biological activities of its constituent proteins. Different bioactivities have 37 
been associated to these proteins among them antihypertensive, antimicrobial, opioid, antioxidant 38 
and immunomodulant activity being the most studied. Although biological activities are present in 39 
the intact proteins, in many cases whey proteins act as precursors of bioactive peptides that are 40 
released from the hydrolysis of these proteins with different enzymes. This review presents an 41 
overview of the different biological activities described for caprine and ovine cheese whey proteins 42 
as well as for other whey components such as lactose, oligosaccharides or minerals.  43 
 44 
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1. Introduction 57 
Goat and sheep milk have traditionally been a vital part of the cultural heritage and national 58 
economy of Mediterranean countries, particularly France, Italy, Spain and Greece. Rearing goats 59 
and sheep is gaining importance worldwide, and the production of derived dairy products have 60 
experienced an important increase, making them of particular economic value in these countries 61 
(Pandya and Ghodke, 2007; Raynal-Ljutovac et al., 2008). Excellent cheeses are made with goat 62 
and sheep milk. Some of the best known are Roquefort, Peccorino Romano, Feta, Manchego, 63 
Bryndza and the French goat milk cheeses. Specific texture and taste of sheep and goat milk, as 64 
well as their nutritional and functional properties, have made them a valuable and healthier 65 
alternative to cow milk. Even, many authors have called them “functional foods” because of their 66 
modulating activity of physiological functions and their reducing properties of chronic diseases risk 67 
(Correia and Cruz, 2006).  68 
The average protein content in sheep milk (5.8%, w/w) is higher than in goat (4.6%, w/w) or 69 
cow milk (3.3%, w/w). Whey is the soluble fraction of milk, rich in proteins, minerals and lactose 70 
that are separated from casein during the manufacture of cheese or casein. Rennet-driven 71 
coagulation releases the sweet whey or cheese whey, while that obtained from the mineral or lactic 72 
acid coagulated casein is called acid whey. Whey from ovine and caprine species have a unique 73 
protein composition that depends on factors, such as the type of whey (acid or sweet), the time of 74 
the year, the type of feed, the stage of lactation and the quality of processing. Distribution of 75 
individual proteins in sheep and goat milk whey and its comparison with cow milk is shown in 76 
Table 1. The major whey proteins are -lactoglobulin ( -Lg) and -lactalbumin ( -La). 77 
Immunoglobulins (Igs), serum albumin and proteose–peptones are present in smaller 78 
concentrations. Another soluble protein found in small amounts is lactoferrin (LF) and, in the case 79 
of rennet whey, caseino-macropeptide (CMP) is also present. Other components including lactose, 80 
oligosaccharides or minerals are also important in the whey. 81 
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  Traditionally, whey has been viewed as a by-product of dairy industry with little value for the 82 
consumers. However, in last decades, there is a growing interest focused on the nutritional 83 
properties of whey proteins and whey-derived products and its role upon human health. Milk whey 84 
proteins exhibit a range of biological activities that influence digestion, metabolic responses to 85 
absorbed nutrients, growth and development of specific organs, and resistance to disease. Moreover, 86 
hydrolysis of these proteins can release fragments, termed bioactive peptides, capable to exert 87 
specific biological activities, such as antihypertensive, antimicrobial, opioid, antioxidant, 88 
immunomodulant, or mineral binding (Yalcin, 2006; Hernández-Ledesma et al., 2008; Madureira et 89 
al., 2010). Unlike casein-derived bioactive peptides that can be released by either technological 90 
process during food production (e.g. cheese) or by enzymatic hydrolysis, whey protein-derived 91 
bioactive peptides are mainly produced by the second step using different enzymes or by chemical 92 
synthesis (Morris and Fitzgerald, 2008). Compared to bovine proteins, only few reports have been 93 
focused on peptides released from ovine and caprine milk whey proteins. Since primary structures 94 
of these proteins show a great homology with those observed for bovine proteins (see primary 95 
structure of -Lg as an example, Figure 1), it is predictable that ovine and caprine whey proteins 96 
could also exert as source of numerous bioactive peptides. This review will be focused on the most 97 
recent research advances pertaining to the biological properties of ovine and caprine whey proteins 98 
and derived-peptides. Moreover, bioactivity of other components of cheese whey, such as lactose, 99 
oligosaccharides and minerals will be also included in this review.  100 
 101 
2. Whey proteins 102 
Nowadays, whey proteins are used in a variety of products appealing to nutrition-103 
conscious
 
consumers and for athletes. They can be consumed as ready-to-drink and powdered 104 
beverages, sport meals, nutrition bars, high-protein cookies
 
and in tablet form. One of the reasons to 105 
explain the high consumption of this kind of products is that whey protein has been reported to 106 
support net muscle mass gains
 
with resistance exercise (Phillips et al., 2009). In addition, whey 107 
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protein seems to have potential as a functional food component to contribute to the regulation of 108 
body weight by providing satiety signals that affect both short-term and long-term food intake 109 
regulation (Luhovyy et al., 2007). Other physiological activities of the individual whey protein, 110 
some of them shared with peptides derived from their hydrolysis, are described in this review. 111 
 112 
2.1. -lactoglobulin  113 
-Lg is the major whey protein found in cow, sheep, goat and other ruminants’ milk. 114 
Concentration of ovine and caprine -Lg varies from 2.7 to 5.0 g/L and from 1.8 to 2.8 g/L, 115 
respectively, whereas concentration of this protein from bovine origin varied varies between 2.3 g/L 116 
and 4.9 g/L (Table 1). -Lg is a small, soluble and globular protein, containing 162 amino acids in a 117 
single peptide chain with a molecular weight of 18.3 kDa. The primary sequence reveals two intra-118 
chain disulphide bridges (Cys66-Cys160 and Cys106-Cys-119) and a free thiol group at Cys121 119 
(Creamer et al., 1983). Reported activities for -Lg are summarized in Table 2. The homology of -120 
Lg tertiary structure with the plasma retinol-binding protein as well as its high stability to 121 
proteolytic action of digestive enzymes has suggested the role of this protein as a resistant carrier of 122 
retinol (a provitamin A). Moreover, fatty acid binding sites characterised on -Lg allow this protein 123 
to participate in the digestion of milk lipids during the neonatal period. In addition, it has been 124 
shown that -Lg enhances intestinal uptake of retinol, triglycerides, and long-chain fatty acids in 125 
pre-ruminant calves (Kushibiki et al., 2001), and it has been speculated that this protein may play a 126 
role in the absorption and subsequent metabolism of fatty acids. Other possible functions have been 127 
described for this whey protein, such as its role in developing passive immunity with IgG (Sutton 128 
and Alston-Mills, 2006). Wong and co-workers (1998) demonstrated that this whey protein 129 
stimulates normal murine spleen cells proliferation and Igs production. Moreover, -Lg is a rich 130 
source of Cys, an essential amino acid that appears to stimulate glutathione synthesis, an 131 
anticarcinogenic tripeptide produced by the liver for protection against intestinal tumors (Mcintosh 132 
et al., 1995). The high nutritional and functional value of -Lg is widely recognized and has made 133 
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this protein an ingredient of choice in the formulation of modern foods and beverages (Chatterton et 134 
al., 2006).  135 
2.2. -lactalbumin 136 
-La is a metalloprotein that contains one atom of Ca per molecule and is physiologically 137 
important because of its requirements in lactose synthesis. While the concentration of bovine -La 138 
varies between 0.8 g/L and 1.2 g/L, in goat milk is present at concentrations around 0.6-1.1 g/L and 139 
in ovine milk ranges between 1.2 g/L and 2.6 g/L (Table 1). -La is a small and globular protein of 140 
approximately 14 kDa that consists of a single polypeptide chain with eight cysteine residues which 141 
form four disulphide bridges (Cys25-Cys139, Cys47-Cys-130, Cys80-Cys96 and Cys92-Cys110). Both 142 
sheep and goat -La possesses high homology with its bovine counterpart. 143 
Some important bioactivities have been reported for -La (Table 2). The best known is the 144 
anti-tumoral activity observed for the complex between human -La and oleic acid called 145 
HAMLET (human alpha-lactalbumin made lethal to tumor cells). This complex is able to kill 146 
tumour cells by a process resembling programmed cell death. HAMLET has broad antitumor 147 
activity in vitro, and its therapeutic effect has been confirmed in vivo in a human glioblastoma rat 148 
xenograft model, in patients with skin papillomas and in patients with bladder cancer (Hallgren et 149 
al., 2008). Likewise, a complex of bovine -La and oleic acid (BAMLET) killed tumor cells via a 150 
mechanism involving lysosomal membrane permeabilization,  showing potent cytotoxic activity 151 
against eight different cancer cell lines (Rammer et al., 2010) 152 
 153 
2.3. Serum albumin 154 
Serum albumin is a 582 amino acids-protein that appears in milk after its passive leakage 155 
from blood. It possesses 17 intermolecular disulphide bridges and one free thiol group. Because of 156 
its size and structure, serum albumin binds free fatty acids, participating in synthesis of lipids (Choi 157 
et al., 2002). Moreover, its antioxidant activity has been reported to be effective on protecting lipids 158 
against phenolic induced oxidation (Smith et al., 1992). Laursen and co-workers (1990) revealed 159 
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serum albumin’s inhibitory activity of breast cancer cells proliferation through modulation of 160 
autocrine growth regulatory factors (Table 2).  161 
2.4. Lactoferrin 162 
LF, also known as lactotransferrin, is a globular multifunctional protein that binds, 163 
transports and supplies the organism with iron. The iron binding properties seem to vary between 164 
LF from different species (Sreedhara et al., 2010). The levels of this protein in sheep and goat milk 165 
are slightly higher than in cow milk, with values of approximately 0.1 mg/mL and 0.125 mg/mL, 166 
respectively (Table 1) (El-Agamy and Nawar, 2000). Traditionally it has been recognized to possess 167 
antimicrobial and antifungal properties (Orsi, 2004; Olakanimi et al., 2002; Table 2). LF exerts its 168 
antimicrobial activity by two different mechanisms. A bacteriostatic effect through the binding of 169 
iron ions necessary for cell growth, and a bactericidal effect similar for Gram-negative and Gram-170 
positive bacteria involving direct interaction with the bacterial cell membrane (Ling and Schryvers, 171 
2006). 172 
Recent research has revealed that bovine LF induced apoptosis of human stomach cancer 173 
cells (Xu et al., 2010). LF also displays antiviral activity against both DNA- and RNA-viruses 174 
preventing their entry in the host cell either by blocking cellular receptors or by direct binding to the 175 
virus particles (Van der Strate et al., 2001, Seganti et al., 2004). Some in vivo studies have shown 176 
that LF exerts a protective effect against colitis in rats via modulation of the immune system and 177 
correction of cytokine imbalance (Togawa et al., 2002). Finally, purified ovine LF and its pepsin 178 
hydrolyzate inhibit thrombin-induced platelet aggregation (Quian et al., 1995a). 179 
 180 
2.5. Caseinomacropeptide 181 
CMP is composed by the 64 C-terminal amino acids of κ-casein, and it is released by 182 
chymosin (or pepsin) cleavage of κ-casein during cheese manufacturing. From a nutritional point of 183 
view, the CMP possesses limitations due to the lack of several essential amino acids (arginine, 184 
cysteine, histidine, tryptophan and tyrosine).  However, its unique amino acid composition makes it 185 
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adequate for special diets, for instance in phenylketonuria patients’ diets since no phenylalanine is 186 
present. Additionally, CMP is rich in branched-chain amino acids (valine and isoleucine) and low in 187 
methionine, which makes it a useful ingredient in diets for patients suffering from hepatic diseases 188 
(Abd El-Salam et al., 1996). The biological properties of the CMP have received much attention in 189 
recent years (see review Thomä-Worringer et al., 2006). CMP is able to interact with toxins, viruses 190 
and bacteria due to its carbohydrate fraction, preventing the binding of different pathogens to cells 191 
or the adhesion of bacteria implicated in cariogenic processes (Manso and López-Fandiño, 2004). A 192 
recent study has demonstrated the CMP’s protecting effect against acidic erosion of teeth 193 
(Setarehnejad et al., 2010). CMP also exerts inmunomodulating and prebiotic activity (Mikkelsen et 194 
al., 2006).  195 
 196 
2.6. Other proteins 197 
Ovine and caprine milk whey contain minor proteins, including Igs, transferrin, ferritin, 198 
proteose peptone, lactoperoxidase, lysozyme, calmodulin (calcium binding protein), prolactin and 199 
folate-binding protein (Park et al., 2007). Igs constitute a complex group of globular proteins 200 
produced by B-lymphocytes, consisting of two light polypeptide chains (with a molecular weight of 201 
25,000 kDa) and two heavy chains (with molecular weight in the range from 50,000 to 70,000 kDa). 202 
They protect the gut mucosa against pathogenic microorganisms, also providing protection against 203 
diseases in the ruminant neonate until its own immune system is developed. Recently, it has been 204 
demonstrated that oral administration of ovine serum Ig modulates aspects of immunity, such as 205 
phagocytosis, lymphocyte proliferation, cytokine production, intestinal and plasma Ig 206 
concentrations in growing rats (Balan et al., 2010). These authors had previously reported the effect 207 
of this ovine Ig fraction improving growth performance, organ weight and gut morphology in 208 
growing rats (Balan et al., 2009). 209 
Lactoperoxidase is one of the most abundant enzymes in plain milk, representing 1% (w/w) 210 
of the total protein pool in whey. It is an important part of the natural host defence system in 211 
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mammals, which provides protection against invading microorganisms and virus (de Wit & van 212 
Hooydonk, 1996; Shin et al., 2005; Table 2). This enzyme, combined with lactoferrin in a cell 213 
culture, has also been reported to have suppressive effects on mitogen-activated lymphocyte 214 
proliferation through inhibition of IFN-  production (Wong et al., 1997; Mercier et al., 2004). 215 
Recent studies have demonstrated that lactoperoxidase acts regulating expression of genes involved 216 
in metabolism, immunity, apoptosis, and cell cycle of epithelial intestinal cells (Wakabayashi et al., 217 
2007). 218 
 Protease-peptone is defined as a heat-stable and acid-soluble fraction of milk whey. 219 
Lactophorin is a minor phosphoglycoprotein corresponding to component-3 of protease peptone 220 
found in bovine, ovine and caprine milk (Lister et al., 1998). It has been demonstrated to have 221 
immunomodulatory properties, being effective on IgM production of hybridoma cells (Sugahara et 222 
al., 2005). The C-terminal region f(113-135) of lactophorin, called lactophoricin, has been reported 223 
to display growth inhibitory activity against both Gram-positive and Gram-negative bacteria 224 
(Campagna et al., 2004).  225 
 226 
3. Bioactive peptides derived from whey proteins 227 
3.1. Antihypertensive peptides 228 
During last years, food scientists and technologists have focused their studies on 229 
bioactivities associated with whey protein-derived peptides. Among the bioactive peptides known 230 
so far, those with angiotensin converting enzyme (ACE)-inhibitory properties have received special 231 
attention due their potential beneficial effects in the treatment of hypertension. Most published 232 
reports on ACE-inhibitory and/or antihypertensive peptides are associated with peptides derived 233 
from bovine milk. However, in recent years, sheep and goat milk whey proteins have become an 234 
important source of ACE-inhibitory peptides (Table 3). In a study where a caprine -Lg hydrolyzate 235 
was prepared using thermolysin as proteolytic enzyme, two potent ACE-inhibitory peptides, which 236 
sequences were LLF and LQKW, were identified (Hernández-Ledesma et al., 2002). Subsequently, 237 
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the antihypertensive effect of these two peptides in spontaneously hypertensive rats (SHR) has been 238 
reported (Hernández-Ledesma et al., 2007). Chobert and coworkers (2005) investigated the ACE-239 
inhibitory activity of ovine -Lg hydrolysed with trypsin, and of yoghurts made from ovine milk 240 
using different starters. These authors identified in this hydrolyzate several peptides responsible for 241 
this activity (Table 3).  242 
Although less explored than -Lg, several ACE-inhibitory peptides from -La have been 243 
identified by different authors. Mullaly et al. (1996) synthesized three peptides from -La sequence, 244 
YG, YGLF and LF, and studied their ACE-inhibitory activity. Despite none of these peptides 245 
showed very strong inhibitory activity, the cardiovascular effects of the tetrapeptide YGLF, known 246 
as α-lactorphin, was later tested in SHR and in normotensive Wistar Kyoto rats (WKY). α-247 
Lactorphin, a peptide also produced by enzymatic hydrolysis with pepsin and trypsin, dose-248 
dependently lowered blood pressure without affecting heart rate in SHR and WKY with evidences 249 
for an involvement of opioid receptors in its depressor action (Nurminen et al., 2000). Further 250 
studies to shed light on the antihypertensive mechanism of this tetra-peptide showed that its 251 
beneficial effect was directed towards endothelial function, improving vascular relaxation in adult 252 
SHR in vitro (Sipola et al., 2002). This peptide, α-lactorphin, has been obtained after protein 253 
hydrolysis of caprine -La (Bordenave, 2000).  254 
Didelot et al., (2006) used cheese microflora to produce several hydrolyzates of acid caprine 255 
whey with ACE-inhibitory activity. The highest activity was obtained after whey fermentation by 256 
the microflora from 18-months ripened Comté cheese that was further characterized as a co-culture 257 
of Candida parapsilosis and Lactobacillus paracasei. Fractionation by RP-HPLC and amino acid 258 
analysis allowed the identification of the α-La fragment f(104-108) in the most active fraction 259 
(Table 3). A more recent study also used microorganisms isolated from raw milk cheeses to produce 260 
several hydrolyzates of acid caprine whey with ACE-inhibitory activity, although no peptides were 261 
identified (Hamme et al., 2009).  262 
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ACE-inhibitory peptides have also been identified in hydrolyzates derived from ovine and 263 
caprine CMP. Manso and López-Fandiño (2003), found that undigested bovine, caprine and ovine 264 
CMP exhibited moderate ACE-inhibitory activity, but it increased considerably after digestion 265 
under simulated gastrointestinal conditions. ACE-inhibitory peptides MAIPPK and MAIPPKK, 266 
corresponding to -CN f(106-111) and f(106-112) respectively, were identified from CMPs via 267 
proteolysis with trypsin. These peptides showed moderate activity, but their digestion under 268 
simulated gastrointestinal conditions allowed the release of the potent antihypertensive tri-peptide 269 
IPP (IC50 value of 5 M). 270 
 271 
3.2. Antimicrobial and immunomodulatory peptides 272 
Both in vitro and in vivo studies have demonstrated that certain whey-protein-based 273 
ingredients and individual whey proteins, such as -Lg, can act as precursors of peptides with 274 
antimicrobial activity, enhancing the organism’s natural defences against invading pathogens. 275 
(Rutherfurd-Markwick and Gill, 2005; Gauthier et al., 2006; Saint-Sauveur et al., 2008, 2009). 276 
Recently, the antimicrobial and immunostimulatory activities of -Lg, among other food proteins, 277 
hydrolysed with four gastrointestinal proteinases (trypsin, chymotrypsin, pepsin and pancreatin) 278 
have been examined by Biziulevicius and co-workers (2006). Proteolytic digestion of bovine -Lg 279 
by trypsin allowed the release of four peptide fragments [f(15–20), f(25–40), f(78–83), f(92–100)] 280 
with bactericidal activity against Gram-positive bacteria (Pellegrini et al., 2001). The 281 
immunomodulating potential of peptide fractions isolated from -Lg enzymatic hydrolyzates has 282 
also been demonstrated (Prioult et al., 2004). Recently, peptides corresponding to -Lg fragments 283 
f(15-20), f(55-60), f(84-91), f(92-105), f(139-148), and f(142-148) have been reported to stimulate 284 
murine splenocytes proliferation through the modulation of cytokine secretion (Jacquot et al., 285 
2010). However, few data are reported about the release of antibacterial and/or immunostimulating 286 
peptides from ovine and caprine -Lg. Only a peptic hydrolyzate of ovine -La and -Lg has been 287 
demonstrated by El-Zahar and co-workers (2004) to inhibit the growth of Escherichia coli HB101, 288 
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Bacillus subtilis Cip5262 and Staphylococcus aureus 9973 in a dose dependent manner, but 289 
responsible peptides were not identified. 290 
Additionally, peptides released from LF by enzymatic procedures have been reported with 291 
more potent activity than the precursor protein (Tomita et al., 1991). The antibacterial domains of 292 
bovine LF f(17-41) and human LF f(1-47), called respectively bovine and human lactoferricin 293 
(LFcin), have been purified and identified (Bellamy et al., 1992). These peptides showed a potent 294 
antimicrobial activity against a wide range of Gram-positive and Gram-negative bacteria 295 
(Wakabayashi et al., 2003). Hydrolysis of caprine and ovine LF by pepsin resulted in antibacterial 296 
hydrolyzates, and a homologous peptide to LFcin, corresponding to fragment f(14-42), was 297 
identified in the caprine LF hydrolysate (Table 3). The region corresponding to the LFcin within the 298 
sequence of ovine LF was hydrolysed by the action of pepsin, and hence, the activity observed in 299 
the ovine LF hydrolysate could be caused by other LF fragments (Recio and Visser, 2000). 300 
 301 
3.3. Opioid peptides 302 
Opioid peptides are defined as peptides which have an affinity for an opioid receptor, 303 
exerting opiate-like effects inhibited by naloxone. -Lg has been found to be precursor of several 304 
opioid peptides (Pihlanto-Leppala, 2001). Digestion of bovine -Lg with pepsin and trypsin, or 305 
trypsin and chymotrypsin yielded YLLF, corresponding to fragment f(102–105) and called -306 
lactorphin. A contracting effect of this peptide on smooth muscle has been determined in coaxially 307 
stimulated guinea pig ileum in vitro (Antila et al., 1991). -lactorphin also improved the impaired 308 
vascular function in mesenteric rings of adults SHR (Sipola et al., 2002). This beneficial action was 309 
directed towards endothelial function and also enhanced endothelium-independent relaxation. -310 
lactotensin (HIRL) is a peptide isolated by Yoshikawa and co-workers from a chymotrypsin digest 311 
of -Lg (Yoshikawa et al., 1991). It has a variety of actions including antinociceptive, cholesterol-312 
lowering, anti-stress and memory-enhancing activities (Yamauchi et al., 2003a, b, 2006; Ohinata et 313 
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al., 2007). Recently, it has been found that this peptide also suppresses food intake in mice after its 314 
oral administration (Hou et al., 2009).  315 
 316 
3.4. Other biological activities of whey protein-derived peptides 317 
It is assumed that “oxidative stress” is implicated in the aetiology of age-associated chronic 318 
diseases, such as cardiovascular diseases, diabetes, cataracts, neurodegenerative disorders, certain 319 
types of cancer and aging (Ames et al., 1993). In last few years, the searching for whey-derived 320 
peptides with radical scavenging and lipid peroxidation inhibitory activities is receiving a special 321 
attention. Hernández-Ledesma and co-workers (2005) investigated the antioxidant activity of 322 
hydrolyzates of -Lg by commercial proteases (pepsin, trypsin, chymotrypsin, thermolysin and 323 
corolase PP). These authors found that Corolase PP was the most appropriate enzyme to produce -324 
Lg hydrolyzates having high oxygen radical scavenging activity. Several peptides were identified in 325 
the 3 kDa-permeate from these hydrolyzates. The radical scavenging activity of one of these 326 
peptides, with the sequence WYSLAMAASDI, was slightly higher (2.62 mol Trolox equivs/ mol 327 
peptide) than that shown by the synthetic antioxidant butylhydroxyanisole (BHA) (2.43 mol 328 
Trolox equivs/ mol BHA). 329 
Whey proteins have been reported to exhibit a greater hypocholesterolemic effect in 330 
comparison with casein or soybean proteins in rats (Nagaoka et al., 1991, 1992). A posterior study 331 
of these authors provided the first evidence that -Lg tryptic hydrolyzate had hypocholesterolemic 332 
activity in rats (Nagaoka et al., 2001). By using Caco-2 cell screening, these authors identified four 333 
kinds of novel peptide sequences which inhibited cholesterol absorption in vitro, i.e., IIAEK, 334 
GLDIQK, ALPMH, and VYVEELKPTPEGDLEILLQK, which corresponded, respectively, to 335 
fragments f(71–75), f(9–14), f(142–146), and f(41–60) of bovine -Lg. These peptides are also 336 
present in caprine and ovine -Lg, except for the longest sequence where aspartic acid (D) is 337 
replaced by asparagine (N) in the caprine and ovine sequences.   338 
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Qian et al. (1995b) hydrolysed ovine CMP with trypsin and identified three peptides with 339 
the sequences KDQDK f(112-116), TAQVTSTEV f(163-171) and QVTSTEV f(165-171) that 340 
completely inhibited thrombin-induced human platelet aggregation. Furthermore, bovine, ovine and 341 
caprine CMPs and their hydrolyzates with trypsin were found to be inhibitors of human platelet 342 
aggregation (Manso et al., 2002). In this work, the hydrolyzate obtained from ovine CMP showed 343 
the strongest effect, but the peptides responsible of this activity were not identified.  344 
 345 
4. Other bioactive components in cheese whey 346 
4.1. Lactose and oligosaccharides  347 
Lactose is the major carbohydrate in milk with a content of 4.1 g/100 mL in goat milk and 348 
4.9 g/100 mL in sheep milk (Park et al., 2007). This disaccharide is a valuable nutrient because 349 
favours the intestinal absorption of calcium, magnesium and phosphorous, and the utilization of 350 
vitamin C. On the other hand, milk oligosaccharides possess prebiotic and anti-infective properties. 351 
The amount of oligosaccharides in ovine milk is in the range of 20 mg/mL to 30 mg/mL while in 352 
caprine milk is in the range of 250 mg/mL-300 mg/mL. Many of these oligosaccharides contain 353 
sialic acid, a general name for N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid 354 
(Neu5Gc). Sialic acid present in milk seems to promote the development of the infant’s brain 355 
among other positive effects (Park, 2009). 356 
 357 
4.2. Minerals 358 
Many major and trace minerals play an important role in the physiology and metabolism of 359 
the human body. Sheep has around 0.9 % total minerals or ash, compared to 0.7 % in cow milk. The 360 
most abundant elements are Ca, P, K, Na, and Mg; Zn, Fe, Cu, and Mn are the trace elements. The 361 
levels of Ca, P, Mg, Zn, Fe, and Cu are higher in sheep than in cow milk; the opposite appears to be 362 
the case of K and Na. Goat milk contains about 134 mg of Ca and 121 mg of P/100g. Overall, goat 363 
milk has more Ca, P, K, Mg and Cl, and less Na and S contents than cow milk (Park et al., 2007). 364 
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Na, K, and Cl are almost entirely soluble and fully available in the whey. Ca, Mg, and P are 365 
associated in different proportions to the colloidal suspension of casein micelles and, therefore, are 366 
partly retained in the curd during cheese-making.  367 
 368 
4.3. Vitamins 369 
Vitamins are physiological, biochemical, and metabolical bioactive compounds occurring in 370 
milk. Most of the fat-soluble vitamins are incorporated to the curd during cheese-making while 371 
water-soluble vitamins go mainly to the whey.  In the literature is described than sheep milk is 372 
richer than cow milk for most of the vitamins (Park et al., 2007). For instance, goat and sheep milk 373 
have higher amount of vitamin A than cow milk. However, goat milk has a significant drawback in 374 
folic acid and vitamin B12 compared to cow milk (Park, 2009).  375 
 376 
Final considerations 377 
This review shows the remarkable potential of goat and sheep cheese whey as source and precursor 378 
of bioactive compounds. The traditional view of cheese whey as a by-product of dairy industry with 379 
little value has disappeared, and now the whey is seen as a potential source of bioactive components 380 
that can be used in the formulation of multiple functional foods. Although less explored than bovine 381 
whey, the ovine and caprine counterparts are gaining importance due to the worldwide increase in 382 
the production of dairy products based on the milk of these animals. Among the different 383 
components of cheese whey, proteins are especially important in terms of biological activity. The 384 
advances in processing technology, including ultrafiltration, microfiltration, reverse osmosis or ion 385 
exchange among others, have resulted in the presence of multitude of whey products in the market. 386 
Many of these products, whey powders,
 
reduced lactose whey, whey protein concentrates
, 
etc.., 387 
proclaim their properties to growth or maintenance muscle mass, among other effects. However, as 388 
happens with other claimed activities for whey proteins including their effect on satiation and 389 
satiety, human studies documenting these benefits are limited. Recently, the European Food Safety 390 
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Authority (EFSA) delivered a scientific opinion on different health claims related to whey protein 391 
under Regulation (EC) No 1924/2006. Health claims were rejected based on the absence of human 392 
studies or because the existing ones were inappropriately done (European Food Safety Authority, 393 
2010). Apart from the biological activities of the intact proteins, the recent interest has mainly 394 
focused on bioactive peptides encrypted within the whey proteins that are released by different 395 
means, such as enzymatic hydrolysis and/or fermentation processes. Among the plethora of 396 
bioactivities described for these peptides, stand out some activities like antihypertensive, opioid, 397 
antioxidant, antimicrobial and hypocholesterolemic. Unlike intact whey proteins more research on 398 
bioavailability, toxicity as well as animal studies have been carried out for bioactive peptides. 399 
However, additional studies in both whey protein-based products and those containing whey 400 
bioactive peptides are required in order to gain the official acceptance from EFSA. These studies 401 
should be especially focused on well-designed clinical trials to confirm the potential health effects 402 
of these products.  403 
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- Yoshikawa, M., Sasaki, R., Chiba, H., Tani, F., 1991. Japan Kokai Tokkyo Koho, 220197 (Sep. 679 
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 685 
 686 
Figure legends 687 
Figure 1. Primary structure of -Lg from cow, sheep and goat origin. Marked letters indicate 688 
differences between sequences. 689 
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Table 1. Concentration of the main whey proteins in cow, sheep and goat milk (Storry et al., 1983; Hahn et al., 1998; Fox et al., 2000). 690 
 691 
 692 
 
Concentration (g/L) 
Bovine Ovine Caprine 
Total whey proteins 5.0-9.0 8.8-10.4 3.7-7.0 
-lactoglobulin 3.2-4.0 2.7-5.0 1.8-2.8 
-lactalbumin 1.2-1.5 1.2-2.6 0.6-1.1 
Serum albumin 0.3-0.6 0.55-0.6 0.26-0.3 
Lactoferrin 0.05-0.2 0.10 0.12 
 693 
 694 
 695 
     Table 2. Biological functions of whey proteins 696 
 697 
 698 
Protein Biological function Reference 
-lactoglobulin Carrier of retinol, fatty acids and triglycerides 
Transfer of passive immunity 
Immunomodulatory activity 
Anti-cancerigen activity 
Pérez et al., 1992 
Sutton and Alston-Mills, 2006 
Wong et al., 1998 
Mcintosh et al., 1995 
-lactalbumin Lactose synthesis 
Treatment of chronic stress-induced diseases 
Anti-cancerigen activity 
Markus et al., 2002 
Ganjam et al., 1997 
Hallgren et al., 2008 
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Serum albumin Synthesis of lipids 
Antioxidant activity 
Anti-cancerigen activity 
Choi et al., 2002 
Smith et al., 1992 
Laursen et al., 1990 
Lactoferrin Antimicrobial activity 
Antifungal activity 
Anti-proliferative activity 
Antiviral activity 
Immunomodulatory activity 
Anti-thrombotic activity 
Orsi, 2004 
Olakanimi et al., 2002 
Xu et al.,  2010 
Van der Strate et al., 2001; Seganti et al., 2004 
Togawa et al., 2002 
Quian et al., 1995a 
Caseinomacropeptide Anti-cariogenic activity 
Immunomodulatory activity 
Prebiotic activity 
Anti-thrombotic activity 
 
Oh et al., 2000 ; Kawasaki et al., 1992; 1993 
Otani et al., 1995a, b; 1996 
Azuma  et al., 1984 ; Idota et al., 1994 
Manso et al., 2002 
Immunoglobulins Immunomodulatory activity 
Growth and development  
Balan et al., 2010 
Balan et al., 2009 
Lactoperoxidase Antimicrobial activity 
Antiviral activity 
Immunomodulatory activity 
deWit & van Hooydonk, 1996 
Shin et al., 2005 
Wakabayashi et al., 2007 
Table 3. Sequence of bioactive peptides derived from ovine and caprine milk whey proteins  699 
 700 
 701 
Peptide fragment Sequence Biological activity Produced by References 
-Lg f(58-61) LQKW ACE-inhibitory (3.5 M) 
Antihypertensive 
Hydrolysis with thermolysin Hernández-Ledesma et al. (2002) 
Hernández-Ledesma et al. (2007) 
-Lg f(103-105) LLF ACE-inhibitory (82.4 M) 
Antihypertensive 
Hydrolysis with thermolysin Hernández-Ledesma et al. (2002) 
Hernández-Ledesma et al. (2007) 
-Lg f(142-148) ALPMHIR ACE-inhibitory Tryptic hydrolysis Chobert et al. (2005) 
 
-Lg f(1-8) IIVTQTMK ACE-inhibitory Tryptic hydrolysis Chobert et al. (2005) 
CMP f(112-116)
 
KDQDK Antithrombotic Tryptic hydrolysis Qian et al. (1995b) 
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CMP f(163-171)
 
TAQVTSTEV Antithrombotic  Tryptic hydrolysis Qian et al. (1995b) 
CMP f(165-171)
 
QVTSTEV Antithrombotic Tryptic hydrolysis Qian et al. (1995b) 
CMP f(106-111)
 
MAIPPK ACE-inhibitory              Tryptic hydrolysis Manso et al. (2003) 
CMP f(106-112)
 
MAIPPKK  ACE-inhibitory Tryptic hydrolysis Manso et al. (2003) 
Lactoferrin f(14-42)
 
PEWSKCYQW- 
QRRMRKLGAP- 
SITCVRRTSA 
Antibacterial Hydrolysis with pepsin Recio and Visser, (2000) 
-La (104-108)
 WLAHK ACE-inhibitory Cheese microflora Didelot et al., (2006) 
-La (104-108)
 YGLF ACE-inhibitory (733 M)
a 
Antihypertensive
 d
 
Hydrolysis with pepsin              Bordenave, 2000 
         702 
 
o 
Ovine milk proteins,  703 
g
 Goat milk proteins,  704 
a
 Studies carried out in the bovine peptide 705 
706 
